vs
盖璞（GAP）与徕博科（LH）财务数据对比。点击上方公司名可切换其他公司
盖璞的季度营收约是徕博科的1.1倍（$3.9B vs $3.5B），盖璞净利率更高（6.0% vs 4.7%，领先1.3%），徕博科同比增速更快（5.6% vs 3.0%），徕博科自由现金流更多（$490.3M vs $153.0M），过去两年徕博科的营收复合增速更高（5.2% vs -4.2%）
盖璞（Gap Inc.）是总部位于美国加利福尼亚州旧金山的跨国服饰零售商，1969年由唐纳德·费舍尔与多丽丝·费舍尔创立，旗下拥有Gap、Banana Republic、Old Navy、Athleta四大核心品牌，是美国最大的服饰零售商之一，全球门店数量位列全球第三，仅次于Inditex集团和H&M。
徕博科（Labcorp）是全球领先的生命科学与诊断检测企业，面向医疗机构、制药企业和个人患者提供全面的临床检验服务、药物研发支持及医疗检测解决方案，依托先进科研经验与创新技术输出准确可落地的健康洞察，助力临床决策、加快新药研发，提升全球患者健康水平。
GAP vs LH — 直观对比
营收规模更大
GAP
是对方的1.1倍
$3.5B
营收增速更快
LH
高出2.6%
3.0%
净利率更高
GAP
高出1.3%
4.7%
自由现金流更多
LH
多$337.3M
$153.0M
两年增速更快
LH
近两年复合增速
-4.2%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.9B | $3.5B |
| 净利润 | $236.0M | $164.7M |
| 毛利率 | 42.4% | 28.2% |
| 营业利润率 | 8.5% | 7.6% |
| 净利率 | 6.0% | 4.7% |
| 营收同比 | 3.0% | 5.6% |
| 净利润同比 | -13.9% | 14.9% |
| 每股收益（稀释后） | $0.62 | $1.98 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GAPLH
| Q4 25 | $3.9B | $3.5B | ||
| Q3 25 | $3.7B | $3.6B | ||
| Q2 25 | $3.5B | $3.5B | ||
| Q1 25 | $4.1B | $3.3B | ||
| Q4 24 | $3.8B | $3.3B | ||
| Q3 24 | $3.7B | $3.3B | ||
| Q2 24 | $3.4B | $3.2B | ||
| Q1 24 | $4.3B | $3.2B |
净利润GAPLH
| Q4 25 | $236.0M | $164.7M | ||
| Q3 25 | $216.0M | $261.1M | ||
| Q2 25 | $193.0M | $237.9M | ||
| Q1 25 | $206.0M | $212.8M | ||
| Q4 24 | $274.0M | $143.4M | ||
| Q3 24 | $206.0M | $169.3M | ||
| Q2 24 | $158.0M | $205.3M | ||
| Q1 24 | $185.0M | $228.0M |
毛利率GAPLH
| Q4 25 | 42.4% | 28.2% | ||
| Q3 25 | 41.2% | 28.8% | ||
| Q2 25 | 41.8% | 29.7% | ||
| Q1 25 | 38.9% | 28.3% | ||
| Q4 24 | 42.7% | 26.9% | ||
| Q3 24 | 42.6% | 27.6% | ||
| Q2 24 | 41.2% | 28.8% | ||
| Q1 24 | 38.9% | 28.2% |
营业利润率GAPLH
| Q4 25 | 8.5% | 7.6% | ||
| Q3 25 | 7.8% | 11.1% | ||
| Q2 25 | 7.5% | 11.2% | ||
| Q1 25 | 6.2% | 9.7% | ||
| Q4 24 | 9.3% | 6.5% | ||
| Q3 24 | 7.9% | 7.7% | ||
| Q2 24 | 6.1% | 9.2% | ||
| Q1 24 | 5.0% | 10.1% |
净利率GAPLH
| Q4 25 | 6.0% | 4.7% | ||
| Q3 25 | 5.8% | 7.3% | ||
| Q2 25 | 5.6% | 6.7% | ||
| Q1 25 | 5.0% | 6.4% | ||
| Q4 24 | 7.2% | 4.3% | ||
| Q3 24 | 5.5% | 5.2% | ||
| Q2 24 | 4.7% | 6.4% | ||
| Q1 24 | 4.3% | 7.2% |
每股收益（稀释后）GAPLH
| Q4 25 | $0.62 | $1.98 | ||
| Q3 25 | $0.57 | $3.12 | ||
| Q2 25 | $0.51 | $2.84 | ||
| Q1 25 | $0.53 | $2.52 | ||
| Q4 24 | $0.72 | $1.72 | ||
| Q3 24 | $0.54 | $2.00 | ||
| Q2 24 | $0.41 | $2.43 | ||
| Q1 24 | $0.49 | $2.69 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5B | $532.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.6B | $8.6B |
| 总资产 | $12.4B | $18.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GAPLH
| Q4 25 | $2.5B | $532.3M | ||
| Q3 25 | $2.4B | $598.1M | ||
| Q2 25 | $2.2B | $647.3M | ||
| Q1 25 | $2.6B | $369.4M | ||
| Q4 24 | $2.2B | $1.5B | ||
| Q3 24 | $2.1B | $1.5B | ||
| Q2 24 | $1.7B | $265.1M | ||
| Q1 24 | $1.9B | $99.3M |
股东权益GAPLH
| Q4 25 | $3.6B | $8.6B | ||
| Q3 25 | $3.4B | $8.7B | ||
| Q2 25 | $3.3B | $8.5B | ||
| Q1 25 | $3.3B | $8.3B | ||
| Q4 24 | $3.1B | $8.1B | ||
| Q3 24 | $2.9B | $8.2B | ||
| Q2 24 | $2.7B | $8.0B | ||
| Q1 24 | $2.6B | $8.0B |
总资产GAPLH
| Q4 25 | $12.4B | $18.4B | ||
| Q3 25 | $12.1B | $18.3B | ||
| Q2 25 | $11.6B | $18.1B | ||
| Q1 25 | $11.9B | $17.6B | ||
| Q4 24 | $11.9B | $18.4B | ||
| Q3 24 | $11.5B | $18.6B | ||
| Q2 24 | $10.9B | $16.7B | ||
| Q1 24 | $11.0B | $16.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $299.0M | $614.2M |
| 自由现金流经营现金流 - 资本支出 | $153.0M | $490.3M |
| 自由现金流率自由现金流/营收 | 3.9% | 13.9% |
| 资本支出强度资本支出/营收 | 3.7% | 3.5% |
| 现金转化率经营现金流/净利润 | 1.27× | 3.73× |
| 过去12个月自由现金流最近4个季度 | $779.0M | $1.2B |
8季度趋势，按日历期对齐
经营现金流GAPLH
| Q4 25 | $299.0M | $614.2M | ||
| Q3 25 | $448.0M | $387.2M | ||
| Q2 25 | $-140.0M | $620.6M | ||
| Q1 25 | $616.0M | $18.5M | ||
| Q4 24 | $291.0M | $777.2M | ||
| Q3 24 | $549.0M | $277.3M | ||
| Q2 24 | $30.0M | $561.1M | ||
| Q1 24 | $700.0M | $-29.8M |
自由现金流GAPLH
| Q4 25 | $153.0M | $490.3M | ||
| Q3 25 | $350.0M | $280.5M | ||
| Q2 25 | $-223.0M | $542.7M | ||
| Q1 25 | $499.0M | $-107.5M | ||
| Q4 24 | $143.0M | $665.1M | ||
| Q3 24 | $460.0M | $161.5M | ||
| Q2 24 | $-63.0M | $432.9M | ||
| Q1 24 | $568.0M | $-163.6M |
自由现金流率GAPLH
| Q4 25 | 3.9% | 13.9% | ||
| Q3 25 | 9.4% | 7.9% | ||
| Q2 25 | -6.4% | 15.4% | ||
| Q1 25 | 12.0% | -3.2% | ||
| Q4 24 | 3.7% | 20.0% | ||
| Q3 24 | 12.4% | 4.9% | ||
| Q2 24 | -1.9% | 13.4% | ||
| Q1 24 | 13.2% | -5.2% |
资本支出强度GAPLH
| Q4 25 | 3.7% | 3.5% | ||
| Q3 25 | 2.6% | 3.0% | ||
| Q2 25 | 2.4% | 2.2% | ||
| Q1 25 | 2.8% | 3.8% | ||
| Q4 24 | 3.9% | 3.4% | ||
| Q3 24 | 2.4% | 3.5% | ||
| Q2 24 | 2.7% | 4.0% | ||
| Q1 24 | 3.1% | 4.2% |
现金转化率GAPLH
| Q4 25 | 1.27× | 3.73× | ||
| Q3 25 | 2.07× | 1.48× | ||
| Q2 25 | -0.73× | 2.61× | ||
| Q1 25 | 2.99× | 0.09× | ||
| Q4 24 | 1.06× | 5.42× | ||
| Q3 24 | 2.67× | 1.64× | ||
| Q2 24 | 0.19× | 2.73× | ||
| Q1 24 | 3.78× | -0.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GAP
| Other | $2.2B | 55% |
| Online Sales | $1.6B | 40% |
| CA | $191.0M | 5% |
| Other Regions | $13.0M | 0% |
LH
| Diagnostics | $2.7B | 78% |
| Biopharma Laboratory Services | $793.0M | 23% |
